Bendamustine HCl
Brand Names: Bendamustine HCl Generic
Methodology & AI Transparency ⓘ
Bendamustine HCl Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 100 mg/20mL Injection, Powder, Lyophilized, for Solution and 25 mg/5mL Injection, Powder, Lyophilized, for Solution under FDA code 71288-103, 71288-102 (manufactured/labeled by Meitheal Pharmaceuticals Inc.), Bendamustine HCl delivers intravenous-route alkylating drug pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: Zero-PHI community consensus: 94% favorable across 4 logged regimens (Bendamustine HCl Generic).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $53.46 cash mean against $130.98 retail pharmacy pricing.
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Bendamustine HCl): nausea (7.9%), headache (7.9%), dizziness (5.5%).
Ask our AI Specialists anything about Bendamustine HCl
Bendamustine HCl Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 100 mg/20mL Injection, Powder, Lyophilized, for Solution and 25 mg/5mL Injection, Powder, Lyophilized, for Solution under FDA code 71288-103, 71288-102 (manufactured/labeled by Meitheal Pharmaceuticals Inc.), Bendamustine HCl delivers intravenous-route alkylating drug pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Bendamustine HCl reflects alkylating drug pathway engagement after intravenous-route dosing (100 mg/20mL Injection, Powder, Lyophilized, for Solution and 25 mg/5mL Injection, Powder, Lyophilized, for Solution, manufactured/labeled by Meitheal Pharmaceuticals Inc., NDC 71288-103, 71288-102), supporting titratable maintenance pharmacotherapy.
Pharmacokinetic profiling of Bendamustine HCl demonstrates an elimination half-life of Elimination kinetics span 5 to 18 hours per Bendamustine HCl clinical pharmacology with Complete (~100%) parenteral systemic delivery for Bendamustine HCl (100 mg/20mL Injection, Powder, Lyophilized, for Solution) systemic bioavailability; clearance proceeds via systemic clearance of bendamustine hcl integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after bendamustine hcl administration.
Titration schedules for Bendamustine HCl (100 mg/20mL Injection, Powder, Lyophilized, for Solution → 25 mg/5mL Injection, Powder, Lyophilized, for Solution) require excluding confirmed ige-mediated allergy or cutaneous reaction to bendamustine hcl (bendamustine hcl) components; uncompensated hepatic or renal insufficiency incompatible with bendamustine hcl (100 mg/20ml injection, powder, lyophilized, for solution) clearance; real-world patient logs highlight nausea (7.9% of reports), headache (7.9% of reports), dizziness (5.5% of reports) alongside a 94.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Bendamustine HCl in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Bendamustine HCl maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Bendamustine HCl (Bendamustine HCl) components
- Uncompensated hepatic or renal insufficiency incompatible with Bendamustine HCl (100 mg/20mL Injection, Powder, Lyophilized, for Solution) clearance
Logged Side-Effect Incidence (4 Reports)
Bendamustine HCl Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bendamustine HCl)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine and Exposure-Response Analyses of Ibrutinib 560 mg, combined with BR, consistently improves PFS across the ibrutinib exposure range evaluated. CPT: pharmacometrics & systems pharmacology • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40613748 ↗ |
| New Insights on A phase 3, randomized study of ofatumumab combined with bendamustine in: What a 346-Participant Study Found The study did not meet its primary end-point. British journal of haematology • 2021-06-15 • Phase III Randomized Trial | N = 346 | 87/100 | PMID 33973233 ↗ |
| Can This Approach Help? Inside the Latest Research on Obinutuzumab maintenance versus observation for patients with newly diagnosed Those who achieved complete metabolic response at the end of induction are included in the second registration and randomized to an obinutuzumab maintenance arm or observation only. Japanese journal of clinical oncology • 2025-06-05 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39997358 ↗ |
| Can This Approach Help? Inside the Latest Research on A Phase III open-label randomized study to compare the efficacy of The ORR was similar in both the arms; however, the CR rate was significantly higher in the BR arm. Indian journal of cancer • 2023-10-01 • Phase III Randomized Trial | N = 40 | 82/100 | PMID 38185869 ↗ |
| Can This Approach Help? Inside the Latest Research on Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma Several clinical scenarios were identified where dichotomous immune responses were estimated with >95% confidence based on combinations of predictive variables. British journal of haematology • 2024-08-15 • Phase III Randomized Trial | N = 58 | 82/100 | PMID 38867615 ↗ |
Bendamustine HCl Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1100/unit (~$33.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $130.98 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $53.46 / mo | View logs ↓ |
Bendamustine HCl Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Bendamustine HCl RxNorm Concept ID | RXN-71288103-2904 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $130.98 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $53.46 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Bendamustine HCl Patient Community, Cohort Filters & Dosage Logs
Deterministic Bendamustine HCl reference combining NIH RxNorm (RXN-71288103-2904), Medicaid NADAC ($1.1100/unit), and anonymous cohort outcomes (94% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Bendamustine HCl community threads and patient logs by age, biological sex, dosage, and treatment duration.